Pharmaceutical companies are racing to innovate. But behind the scenes, cybercriminals are racing to exploit.
According to IBM’s 2023 report, pharmaceuticals faced an average ransomware cost of $4.82 million per incident, making it one of the most expensive industries to breach. The probability of ransomware attacks sits at 34%, and attackers are after more than just financial data—they want IP, research, clinical trials, and trade secrets.
So why are so many pharmaceutical companies still relying on periodic control checks?
🔬 The Stakes Are Higher in Pharma
A breach in pharma can:
- Compromise clinical trial data
- Disrupt global drug supply chains
- Expose sensitive patient records
- Delay life-saving treatments
These aren’t just IT risks—they’re public health risks.
Pharmaceutical companies are prime targets not just because of the personal data they hold, but because of the intellectual property they protect—formulas, research data, clinical trial results, and patents. A single breach can not only derail drug development but also hand competitive advantage to bad actors or rival states.
In 2023, a ransomware attack on a leading European pharma group led to operational shutdowns across manufacturing lines in two countries. The fallout? Missed clinical trial deadlines, stock devaluation, and a €7 million compliance fine.
Let’s Talk ROI of Continuous Controls Monitoring
Seeking investment into more tools for a pharmaceuticals cyber security strategy is not an easy task. In any industry – layering more defence can make their ecosystem highly complex. But Continuous Controls Monitoring is that orchestration layer that pulls all those disparate tools together into one single pane of glass – a single source of truth into the effectiveness of your cyber security, risk and compliance posture.
But how can you prove potential ROI? Well we ran the numbers….
And here’s how we broke down the potential ROI
- Probability of Ransomware (P): 34%
- Average Loss per Incident (L): $4.82M
- Annualised Loss Expectancy (ALE): 0.34 x $4.82M = $1.637M
- CCM Risk Reduction (60%):
Risk Avoided = $1.637M x 0.6 = $982.2K - CCM Cost: $100K/year
- ROSI: ($982.2K – $100K) / $100K x 100 = 882.2%
That’s a massive 882% return, or $9.82 saved per $1 spent.
Manual Controls Are a Liability
Pharma companies are complex, regulated, and globally distributed. With GxP, HIPAA, EMA, and FDA to answer to, the cost of non-compliance is steep—and audits are relentless.
Yet many firms still monitor their security controls manually or only before audits.
That means blind spots. And in pharma, blind spots mean breach risks, compliance failures, and production delays.
Why Pharma Needs Continuous Controls Monitoring
- Protection for High-Value IP
R&D data is among the most valuable assets in pharma. CCM helps protect this from unauthorized access and insider threats. - Audit-Readiness at All Times
CCM automates control evidence gathering, making regulatory audits faster, cleaner, and less stressful. - Global Visibility
Whether in labs, manufacturing sites, or distribution centres, CCM gives a real-time view of security posture across regions and vendors.
Secure Innovation Without Delay
Pharma is moving fast—and attackers are too. CCM ensures that security doesn’t slow innovation but accelerates it.
✅ Monitors controls across R&D, production, and compliance
✅ Reduces time-to-response from weeks to minutes
✅ Delivers continuous assurance across global infrastructure
✅ Increases confidence with investors, partners, and regulators
The key Continuous Controls Monitoring business outcomes for pharma:
Here are 5 business outcomes that Continuous Controls Monitoring delivers pharmaceutical organisation:
- IP Protection
Continuous Controls Monitoring ensures that data loss prevention (DLP) tools, access controls, and encryption policies are always enforced and effective—significantly reducing the risk of IP exfiltration. - Audit Readiness and Faster Regulatory Response
Whether it’s GxP, GDPR, or FDA 21 CFR Part 11, CCM helps automate evidence collection, policy mapping, and real-time compliance posture, reducing audit prep time by 60% or more. - Reduced Downtime in Manufacturing
By continuously monitoring OT (Operational Technology) and IT controls, CCM enables faster detection and remediation of threats before they cause manufacturing disruption. - Improved Board-Level Cyber Risk Reporting
Pharma CISOs can use CCM data to translate technical control status into business-impact metrics—enabling informed decisions and faster investment sign-off. - Enhanced Supplier and Third-Party Assurance
With CCM, organisations can continuously assess third-party access, network segmentation, and control compliance, which is critical when working with CROs, manufacturing partners, and distributors.
The ROI is clear. The risk is real. The time is now.
In pharma, the cost of cyberattack isn’t just financial—it’s human.
Continuous Controls Monitoring delivers peace of mind, protects your IP, and ensures resilience at every stage of your value chain. Take the first step, explore more information about our platform here.
